STAT3 and scleroderma: In accordance with our results on a possible circulating “scleroderma” macrophage with M1/M2 phenotype, very recently, Moreno-Moral et al. have found in 57 SSc patients, through RNA sequencing and genome-wide genotyping, a mixed macrophage activation signature, characterized by the downregulation of interferon gamma response, attesting for an M2 polarization, but also by the downregulation of the interleukin (IL)-6/JAK/STAT3 signalling pathway, suggesting for a restricted M2 activity [44].